Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.46 |
| ▸ | CHUK | O15111 | 11/20 | 0.46 |
| ▸ | CIT | O14578 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | AURKAIP1 | Q9NWT8 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.31 |
| ▸ | CCNK | O75909 | 1/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985511 | 0.94 | IKBKB (0.45) | IKBKBCHUKCITCSNK1DMAPK14 | |
| SCHEMBL3414337 | 0.89 | CHUK (0.57) | IKBKBCHUKCITROCK1AURKB | |
| SCHEMBL3411445 | 0.82 | IKBKB (0.55) | IKBKBCHUKCITROCK1AURKB | |
| SCHEMBL2994704 | 0.82 | MAP3K5 (0.45) | IKBKBCHUKCITCSNK1DMAPK14 | |
| SCHEMBL3416702 | 0.79 | IKBKB (0.59) | IKBKBCHUKCITROCK1AURKB | |
| Trifluoroacetic Acid SCHEMBL2991581 | 0.78 | IKBKB (0.61) | IKBKBCHUKCITCSNK1DMAPK14 | |
| SCHEMBL2988183 | 0.78 | IKBKB (0.65) | IKBKBCHUKCITCSNK1DMAPK14 | |
| SCHEMBL3418266 | 0.77 | CIT (0.47) | IKBKBCHUKCITROCK1AURKB | |
| SCHEMBL3417465 | 0.77 | CHUK (0.48) | IKBKBCHUKCITROCK1AURKB | |
| SCHEMBL3413538 | 0.77 | IKBKB (0.54) | IKBKBCHUKCITROCK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | claimed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | IKBKB 11/4885CHUK 22/4885CIT 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.